Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced it has provided a $40 million venture loan facility to Elligo Health Research®, Inc. (“Elligo”), of which $25 million has been initially funded.
Elligo is revolutionizing clinical research with its innovative technology platform, which empowers clients to seamlessly utilize non-traditional clinical trial sites, significantly increasing clients’ access to untapped trial participants. Its data-driven clinical trial recruitment and workflow automation solutions optimize and streamline workflows, while providing users with an integrated and diverse network of relevant clinical trial sites, patients and their own physicians with which to engage.
Elligo is backed by premier investors including Morgan Stanley, Ally Bridge Group, Norwest Venture Partners, Piper Sandler, Noro-Moseley Partners and Hatteras Venture Partners. The company will use the loan proceeds for general growth and working capital purposes.
“Elligo’s cutting-edge technology has the potential to solve the patient accessibility issue that has consistently impacted the clinical trial market,” said Gerald A. Michaud, President of Horizon. “With upwards of 95% of physicians and patients not able to participate in clinical trials, Elligo’s platform presents a compelling opportunity to accelerate clinical research, which is a win for the entire healthcare ecosystem. We are pleased to support Elligo in their ongoing efforts to improve the clinical trial system.”
